{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T08:55:08Z","timestamp":1774083308800,"version":"3.50.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2002,2,1]],"date-time":"2002-02-01T00:00:00Z","timestamp":1012521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2002,2,1]],"date-time":"2002-02-01T00:00:00Z","timestamp":1012521600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Thromb Thrombolysis"],"published-print":{"date-parts":[[2002,2]]},"DOI":"10.1023\/a:1015368126304","type":"journal-article","created":{"date-parts":[[2002,12,28]],"date-time":"2002-12-28T18:08:17Z","timestamp":1041098897000},"page":"41-47","source":"Crossref","is-referenced-by-count":55,"title":["Argatroban"],"prefix":"10.1007","volume":"13","author":[{"given":"Sekar","family":"Kathiresan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin","family":"Shiomura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ik-Kyung","family":"Jang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"405595_CR1","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1152\/ajplegacy.1916.41.2.250","volume":"41","author":"J. McLean","year":"1916","unstructured":"McLean J. The thromboplastic action of cephalin. Am J Physiol 1916;41:250\u2013257.","journal-title":"Am J Physiol"},{"key":"405595_CR2","doi-asserted-by":"crossref","first-page":"258S","DOI":"10.1378\/chest.108.4_Supplement.258S","volume":"108","author":"J Hirsh","year":"1995","unstructured":"Hirsh J, Raschke R, Warkentin TE, Dalen JE, Deykin D, Poller L. Heparin: mechanism of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. Chest 1995;108:258S\u2013275S.","journal-title":"Chest"},{"key":"405595_CR3","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1038\/35025229","volume":"407","author":"SR. Coughlin","year":"2000","unstructured":"Coughlin SR. Thrombin signalling and protease-activated receptors. Nature 2000;407:258\u2013264.","journal-title":"Nature"},{"key":"405595_CR4","first-page":"3","volume":"54","author":"MS Sabatine","year":"1999","unstructured":"Sabatine MS, Jang IK. Antithrombotic therapy in acute coronary syndromes. Acta Cardiol 1999;54:3\u201329.","journal-title":"Acta Cardiol"},{"key":"405595_CR5","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1067\/mhj.2001.117031","volume":"142","author":"J. Hirsh","year":"2001","unstructured":"Hirsh J. New anticoagulants. Am Heart J 2001;142:S3\u2013S8.","journal-title":"Am Heart J"},{"key":"405595_CR6","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1055\/s-2007-996128","volume":"23","author":"MJ Hursting","year":"1997","unstructured":"Hursting MJ, Alford KL, Becker JC, et al. Novastan (brand of argatroban): a small molecule, direct thrombin inhibitor. Semin Thromb Hemost 1997;23:503\u2013516.","journal-title":"Semin Thromb Hemost"},{"key":"405595_CR7","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1055\/s-0038-1648875","volume":"72","author":"CN Berry","year":"1994","unstructured":"Berry CN, Girardot C, Lecoffre C, Lunven C. Effects of the synthetic thrombin inhibitor argatroban on fibrinor clot-incorporated thrombin: comparison with heparin and recombinant hirudin. Thromb Haemost 1994;72:381\u2013386.","journal-title":"Thromb Haemost"},{"key":"405595_CR8","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1182\/blood.V92.6.2064","volume":"92","author":"RR Hantgan","year":"1998","unstructured":"Hantgan RR, Jerome WG, Hursting MJ. No effect of clot age or thrombolysis on argatroban' inhibition of thrombin. Blood 1998;92:2064\u20132074.","journal-title":"Blood"},{"key":"405595_CR9","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1345\/aph.10301","volume":"35","author":"LM Kondo","year":"2001","unstructured":"Kondo LM, Wittkowsky AK, Wiggins BS. Argatroban for the prevention and treatment of thromboembolism in heparin-induced thrombocytopenia. Ann Pharmacother 2001;35:440\u2013451.","journal-title":"Ann Pharmacother"},{"key":"405595_CR10","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1592\/phco.20.9.756.35194","volume":"20","author":"SK Swan","year":"2000","unstructured":"Swan SK, St Peter JV, Lambrecht LJ, Hursting MJ. Comparison of anticoagulant effects and safety of argatroban and heparin in healthy subjects. Pharmacotherapy 2000;20:756\u2013770.","journal-title":"Pharmacotherapy"},{"key":"405595_CR11","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1592\/phco.20.4.318.34881","volume":"20","author":"SK Swan","year":"2000","unstructured":"Swan SK, Hursting MJ. The pharmacokinetics and pharmacodynamics of argatroban: effects of age, gender, and hepatic or renal dysfunction. Pharmacotherapy 2000;20:318\u2013319.","journal-title":"Pharmacotherapy"},{"key":"405595_CR12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/107602969700300101","volume":"3","author":"RP Schwartz","year":"1997","unstructured":"Schwartz RP, Becker JP, Brooks RL, et al. The preclinical and clinical pharmacology of Novastan (argatroban): a small molecule, direct thrombin inhibitor. Clin Appl Thromb Hemost 1997;3:1\u201315.","journal-title":"Clin Appl Thromb Hemost"},{"key":"405595_CR13","unstructured":"Data on file. Argatroban Prescribing Information. Philadelphia: Smith-Kline Beecham, 2000."},{"key":"405595_CR14","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/0006-291X(81)91279-1","volume":"101","author":"S Okamoto","year":"1981","unstructured":"Okamoto S, Hijikata A, Kikumoto R, et al. Potent inhibition of thrombin by the newly synthesized arginine derivative No. 805: the importance of stereostructure of its hydrophobic carboxamide portion. Biochem Biophys Res Commun 1981;101:440\u2013446.","journal-title":"Biochem Biophys Res Commun"},{"key":"405595_CR15","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1161\/01.RES.67.6.1552","volume":"67","author":"IK Jang","year":"1990","unstructured":"Jang IK, Gold HK, Leinbach RC, Fallon JT, Collen D. In vivo thrombin inhibition enhances and sustains arterial recanalization with recombinant tissue-type plasminogen activator. Circ Res 1990;67:1552\u20131561.","journal-title":"Circ Res"},{"key":"405595_CR16","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1161\/01.CIR.81.1.219","volume":"81","author":"IK Jang","year":"1989","unstructured":"Jang IK, Gold HK, Ziskind AA, Leinbach RC, Fallon JT, Collen D. Prevention of platelet-rich arterial thrombosis by selective thrombin inhibition. Circulation 1989;81:219\u2013225.","journal-title":"Circulation"},{"key":"405595_CR17","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1097\/00019501-199205000-00009","volume":"3","author":"IK Jang","year":"1992","unstructured":"Jang IK, Gold HK, Leinbach RC, et al. Persistent inhibition of arterial thrombosis by a 1-hour intravenous infusion of argatroban, a selective thrombin inhibitor. Coron Artery Dis 1992;3:407\u2013414.","journal-title":"Coron Artery Dis"},{"key":"405595_CR18","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/0735-1097(90)90364-U","volume":"16","author":"T Yasuda","year":"1990","unstructured":"Yasuda T, Gold HK, Yaoita H, et al. Comparative effects of aspirin, a synthetic thrombin inhibitor and a monoclonal antiplatelet glycoprotein IIb\/IIIa antibody on coronary artery reperfusion, reocclusion, and bleeding with recombinant tissue-type plasminogen activator in a canine preparation. J Am Coll Cardiol 1990;16:714\u2013722.","journal-title":"J Am Coll Cardiol"},{"key":"405595_CR19","first-page":"1880","volume":"33","author":"IK Jang","year":"1999","unstructured":"Jang IK, Brown DF, Giugliano RP, et al. A multi-center, randomized study of argatroban versus heparin as adjunct to tissue plasminogen activator (tPA) in acute myocardial infarction: myocardial infarction with novastan and tPA (MINT) study. J Am Coll Cardiol 1999;33:1880\u20131885.","journal-title":"J Am Coll Cardiol"},{"key":"405595_CR20","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1023\/A:1026591023462","volume":"10","author":"F Vermeer","year":"2000","unstructured":"Vermeer F, Vahanian A, Fels PW, et al. Argatroban and alteplase in patients with acute myocardial infarction: the ARGAMI study. J Thromb and Thrombolysis 2000;10:233\u2013240.","journal-title":"J Thromb and Thrombolysis"},{"issue":"1","key":"405595_CR21","first-page":"I453","volume":"98","author":"S Behar","year":"1998","unstructured":"Behar S, Hod H, Kaplinsky E, for the ARGAMI-2 Study Group. Argatroban versus heparin as adjuvant therapy to thrombolysis for acute myocardial infarction: safety considerations-ARGAMI-2 study [abstract]. Circulation 1998;98(1, suppl):I453\u2013I454.","journal-title":"Circulation"},{"key":"405595_CR22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0735-1097(97)00195-2","volume":"30","author":"RJ- Cody","year":"1997","unstructured":"Cody RJ-Results from late breaking clinical trials session at ACC'97. J Am Coll Cardiol 1997;30:1\u20137.","journal-title":"J Am Coll Cardiol"},{"key":"405595_CR23","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1016\/0735-1097(93)90222-M","volume":"21","author":"HK Gold","year":"1993","unstructured":"Gold HK, Torres FW, Garabedian HD, et al. Evidence for a rebound coagulation phenomenon after cessation of a 4-hour infusion of a specific thrombin inhibitor in pa-tients with unstable angina pectoris. J Am Coll Cardiol 1993;21:1039\u20131047.","journal-title":"J Am Coll Cardiol"},{"key":"405595_CR24","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1056\/NEJM199207163270301","volume":"327","author":"P Theroux","year":"1992","unstructured":"Theroux P, Waters D, Lam J, Juneau M, McCans J. Reactivation of unstable angina after the discontinuation of heparin. N Engl J Med 1992;327:141\u2013145.","journal-title":"N Engl J Med"},{"key":"405595_CR25","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1023\/A:1008979010033","volume":"7","author":"JL Januzzi","year":"1999","unstructured":"Januzzi JL, Jang IK. Heparin induced thrombocytopenia: diagnosis and contemporary antithrombin management. J Thromb and Thrombolysis 1999;7:259\u2013264.","journal-title":"J Thromb and Thrombolysis"},{"key":"405595_CR26","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1161\/01.CIR.103.14.1838","volume":"103","author":"BE Lewis","year":"2001","unstructured":"Lewis BE, Wallis DE, Berkowitz SD, et al. Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia. Circulation 2001;103:1838\u20131843.","journal-title":"Circulation"},{"key":"405595_CR27","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/BF00133080","volume":"3","author":"JR Herrman","year":"1996","unstructured":"Herrman JR, Suryapranata H, den Heijer P, Gabriel L, Kutryk MJ, Serruys PW. Argatroban during percutaneous transluminal coronary angioplasty: results of a dose-verification study. J Thromb and Thrombolysis 1996;3:367\u2013375.","journal-title":"J Thromb and Thrombolysis"},{"issue":"8","key":"405595_CR28","first-page":"I217","volume":"96","author":"BE Lewis","year":"1997","unstructured":"Lewis BE, Matthai W, Grassman ED, et al. Results of a Phase 2\/3 trial of argatroban anticoagulation during PTCA of patients with heparin-induced thrombocytopenia [abstract]. Circulation 1997;96(8, suppl 1):I217.","journal-title":"Circulation"},{"key":"405595_CR29","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1055\/s-2007-996131","volume":"23","author":"S Kobayashi","year":"1997","unstructured":"Kobayashi S, Tazaki Y. Effect of the thrombin inhibitor argatroban in acute cerebral thrombosis. Semin Thromb and Hemost 1997;23:531\u2013534.","journal-title":"Semin Thromb and Hemost"},{"key":"405595_CR30","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/BF01064381","volume":"2","author":"T Matsuo","year":"1995","unstructured":"Matsuo T, Kario K, Matsuda S, Yamaguchi N, Kakishita E. Effect of thrombin inhibition on patients with peripheral arterial obstructive disease: a multicenter clinical trial of argatroban. J Thromb Thrombolysis 1995;2:131\u2013136.","journal-title":"J Thromb Thrombolysis"},{"key":"405595_CR31","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/BF03218083","volume":"48","author":"H Ohteki","year":"2000","unstructured":"Ohteki H, Furukawa K, Ohnishi H, Narita Y, Sakai M, Doi K. Clinical experience of argatroban for anticoagulation in cardiovascular surgery. Jpn J Thorac Cardiovasc Surg 2000;48:39\u201346.","journal-title":"Jpn J Thorac Cardiovasc Surg"},{"key":"405595_CR32","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/S0889-8588(05)70144-1","volume":"14","author":"T Kawada","year":"2000","unstructured":"Kawada T, Kitagawa H, Hoson M, Okada Y, Shiomura J. Clinical application of argatroban as an alternative anticoagulant for extracorporeal circulation. Hematol Oncol Clin North Am 2000;14:445\u2013457.","journal-title":"Hematol Oncol Clin North Am"},{"key":"405595_CR33","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1093\/clinchem\/45.3.409","volume":"45","author":"MJ Hursting","year":"1999","unstructured":"Hursting MJ, Zehnder JL, Joffrion JL, Becker JC, Knappenberger GD, Schwarz RP. The international normalized ratio during concurrent warfarin and argatroban anticoagulation: differential contributions of each agent and effects of the choice of thromboplastin used. Clin Chem 1999;45:409\u2013412.","journal-title":"Clin Chem"},{"key":"405595_CR34","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1055\/s-0037-1615601","volume":"85","author":"SB Sheth","year":"2001","unstructured":"Sheth SB, DiCicco RA, Hursting MJ, Montague T, Jorkasky DK. Interpreting the international normalized ratio (INR) in individuals receiving argatroban and warfarin. Thromb Haemost 2001;85:435\u2013440.","journal-title":"Thromb Haemost"},{"key":"405595_CR35","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1056\/NEJM200106213442501","volume":"344","author":"CP Cannon","year":"2001","unstructured":"Cannon CP, Weintraub WS, Demopoulos LA, et al. TACTICS (treat angina with aggrastat and determine cost of therapy with an invasive or conservative strategy)- Thrombolysis In Myocardial Infarction 18 investigators: comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb\/IIIa inhibitor tirofiban. N Engl J Med 2001;344:1879\u20131887.","journal-title":"N Engl J Med"}],"container-title":["Journal of Thrombosis and Thrombolysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1023\/A:1015368126304.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1023\/A:1015368126304\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1023\/A:1015368126304.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,8]],"date-time":"2025-08-08T07:31:09Z","timestamp":1754638269000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1023\/A:1015368126304"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,2]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2002,2]]}},"alternative-id":["405595"],"URL":"https:\/\/doi.org\/10.1023\/a:1015368126304","relation":{},"ISSN":["0929-5305","1573-742X"],"issn-type":[{"value":"0929-5305","type":"print"},{"value":"1573-742X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,2]]}}}